CVRx, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- CVRx, Inc. is a commercial-stage medical device company specializing in the development, manufacturing, and commercialization of neuromodulation solutions for patients with cardiovascular diseases. The company’s core product is the Barostim system, an implantable device designed to treat hypertension and heart failure by electrically stimulating the body's natural baroreceptors to regulate blood pressure and cardiovascular function. The product portfolio includes the second-generation Barostim Neo2 implantable pulse generator and associated implantable systems, which provide personalized, non-destructive, and reversible treatment with 100% patient compliance. CVRx distributes its products primarily through a direct sales force in the United States, supported by over 250 active implanting centers and an expanding footprint of 48 sales territories. Founded in 2001 and headquartered in Minneapolis, Minnesota, CVRx operates primarily in the U.S. market with ongoing clinical evaluations and regulatory developments in Europe. The company targets patients with resistant hypertension and heart failure, with a strategic focus on increasing physician and patient awareness, improving access to therapy, and expanding clinical evidence. Recent developments include the launch of their second-generation Barostim Neo2 pulse generator in late 2022, offering enhanced treatment options for heart failure symptoms. In 2024 and 2025, CVRx demonstrated robust commercial growth, increasing U.S. active implanting centers from 208 to 250 and expanding sales territories. CVRx’s latest major strategic activities include raising $12.8 million through at-the-market offerings to support commercial expansion and marketing initiatives focused on salesforce growth and territory development. The company achieved 35% revenue growth in 2024 with forecasted total revenue between $63 million and $65 million for 2025. CVRx continues investment in enhancing its sales and marketing organization to support broader market penetration and patient uptake of Barostim therapy. These operational expansions position CVRx as a leader in implantable neuromodulation therapies for cardiovascular conditions. Overall, CVRx operates in the medical device and healthcare industry, with a clear commercial-stage focus on innovative neuromodulation treatments for cardiovascular diseases. The company maintains a strong emphasis on product innovation, clinical validation, and geographic expansion within the United States, while also exploring opportunities in European markets. CVRx is publicly traded on NASDAQ under the ticker CVRX and maintains proprietary technology centered on baroreceptor activation for improved cardiovascular health outcomes.
Company News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
CVRx Secures Devoted Health Coverage for Barostim Therapy
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
CVRx Responds to Letter from Pointillist Family Office
CVRx, Inc. Investors Who Suffered Losses Should Contact Block & Leviton LLP
Jorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic Acquirer
CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop
CVRx, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop
CVRX ALERT: Securities Fraud Investigation by Block & Leviton Could Allow CVRx, Inc. Investors to Recover Losses
CVRx Eyes Barostim Growth as Coverage Gains and BENEFIT-HF Trial Launches
Securities Fraud Investigation Into CVRx, Inc. (CVRX) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
CVRx, Inc. (CVRX) Shareholders Who Lost Money -- Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
CVRx, Inc. (CVRX) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Securities Fraud Investigation Into CVRx, Inc. (CVRX) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
CVRX INVESTIGATION: CVRx, Inc. Investigated for Securities Fraud by Block & Leviton; Investors Should Contact the Firm to Possibly Recover Losses